Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl's anemia nod

Bristol Myers Squibb and Merck & Co. must wait until the summer at least to learn the fate of Reblozyl’s potential label expansion into anemia from beta thalassemia, BMS said Friday.

The FDA has pushed back its decision on the drug, also known as luspatercept-aamt, by three months. The regulator now plans to issue a verdict on Reblozyl for anemia in adults with non-transfusion-dependent (NTD) beta thalassemia by June 27, Bristol said in a release.